UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal

Moderna's mRNA flu vaccine just cleared its biggest regulatory hurdle — VRBPAC voted unanimously that the benefits outweigh the risks for adults fifty and older, with the PDUFA decision now set for August fifth.

NovoCure's TRIDENT trial misses on overall survival in glioblastoma, shares drop roughly eighteen percent, and Biogen puts up to a billion dollars behind an immunology startup most of the industry has never heard of. Thursday, June eighteenth — let's go.

Welcome to The Pharma Closeout for Thursday, June eighteenth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Plenty to unpack.

As promised yesterday, the full read on Moderna's mFlusiva. VRBPAC voted unanimously on both questions today — benefits outweigh the risks for adults fifty to sixty-four, and separately for sixty-five and older. Not a single dissenting vote on either. After months of regulatory turmoil, the panel's conviction was unambiguous. And I want to underline the word "unambiguous" — advisory committees split votes all the time. They flag dissenting concerns. Here, they chose not to. That unanimity tells you something about how thoroughly Moderna addressed the evidentiary questions that had dogged this program.

What matters more than the vote count is the regulatory architecture underneath it. FDA staff signaled traditional licensure for the fifty to sixty-four cohort and accelerated approval for sixty-five-plus — which locks Moderna into a Phase 4 post-marketing trial head-to-head against high-dose or adjuvanted vaccines in older adults. That Phase 4 commitment is a direct response to the controversy that nearly killed this application earlier in the year. And structurally, it's elegant — the agency gets the confirmatory data it wanted, the company gets to market while that data accrues, and the comparator question that sparked the refuse-to-file is answered prospectively rather than retrospectively.

The arc is worth recounting. In February, then-CBER head Vinay Prasad overruled career FDA staff and issued a refuse-to-file letter, arguing Moderna's pivotal trial used a standard-dose comparator rather than a high-dose or adjuvanted vaccine for the sixty-five-plus arm. Moderna pushed back publicly, produced prior FDA documents showing a standard-dose comparator had been deemed acceptable. Prasad has since departed the agency. The refuse-to-file was reversed. And today the panel endorsed the vaccine unanimously. That sequence — refuse-to-file, public dispute, leadership change, reversal, unanimous endorsement — is extraordinary by FDA standards. It speaks to how disruptive that initial decision was relative to the agency's own precedent.

On efficacy — twenty-six point six percent relative vaccine efficacy against symptomatic flu. Forty-seven point nine percent against medically-attended illness. That gradient — efficacy widening as disease severity increases — is the clinical signal here, not either number alone. When your vaccine performs progressively better the sicker the patient would have gotten, you're selecting for the outcomes that matter most to health systems and to the patients themselves.

Let me push on that. Twenty-six point six percent — if you're a payer reading that topline, you might still call it a modest advance for a platform positioned to redefine flu vaccination. Does that number carry enough weight to justify a formulary disruption?

That reading isolates the wrong endpoint. The near-fifty percent efficacy against medically-attended illness is the metric that tracks real-world disease burden — hospitalizations, clinic visits, system costs. Across more than a hundred and fifty million annual U.S. flu vaccinations, that profile moves population health outcomes meaningfully. The committee understood that, which is why they didn't hesitate. And from a payer perspective, the cost of medically-attended influenza — ER visits, urgent care, lost productivity — dwarfs the incremental cost of switching vaccine platforms. So the pharmacoeconomic case actually strengthens when you focus on the right endpoint.

Regulatory precedent also supports the pathway — multiple flu vaccines currently on the market were first licensed through accelerated approval, a point former FDA officials raised during the public comment period. PDUFA is August fifth. If approved, mFlusiva would be the first mRNA-based seasonal influenza vaccine to reach market, per the company's filings. Sanofi, CSL Seqirus, and GSK have owned U.S. flu vaccination for decades — that competitive map could start shifting fast. And consider the strategic position those incumbents are in — they've been watching mRNA approach their core market for years, and until today the regulatory uncertainty gave them a buffer. That buffer is now gone.

The larger threat to incumbents may not be the efficacy comparison — it's platform economics. If Moderna can show that mRNA manufacturing delivers seasonal vaccines faster or cheaper than egg-based processes, the pressure becomes structural, not just clinical. The speed advantage alone could matter enormously — mRNA doesn't require the six-month egg-based production lead time, which means strain selection can happen closer to flu season, potentially improving antigenic match in years where the virus drifts late. August fifth is the licensure gate. The Phase 4 readout is where the sixty-five-plus picture resolves. But the manufacturing cost story may ultimately be what keeps incumbent CFOs up at night.

Quite a turnaround for Moderna. Shifting to the deal and pipeline side — a starkly different day for NovoCure. The Phase 3 TRIDENT trial missed its primary overall survival endpoint in newly diagnosed glioblastoma. Stock fell approximately eighteen percent.

TRIDENT was the catalyst the entire NovoCure thesis was built on. TTFields carry a label in recurrent GBM, but first-line was the growth story — the reason to own the stock. Without it, the pipeline narrows to other tumor-type expansions with far less commercial upside. And for GBM patients, meaningful treatment progress remains painfully elusive. This is a disease where the standard of care has barely moved in two decades, and TRIDENT represented one of the most credible shots at shifting that trajectory. The miss doesn't just hurt NovoCure's stock — it narrows the near-term horizon for an entire patient population with desperately few options.

The eighteen percent drop prices in a lot of that reality in a single session. Meanwhile, the Biogen-RayThera acquisition we flagged yesterday landed — up to one billion dollars for a secretive immunology startup with preclinical anti-inflammatory assets. Let's bring in Marcus Webb on the structure.

The price tag says more about Biogen's internal pipeline than it does about RayThera's assets. You don't structure a billion-dollar headline for preclinical programs unless your organic options have come up short. Whether these candidates survive the leap from stealth-mode discovery into rigorous clinical development is the real test — and that timeline stretches years, not quarters. The attrition rate for preclinical immunology assets is sobering even under the best circumstances. Biogen is essentially paying for the right to find out whether RayThera's science holds up under that pressure.

Broader capital picture stays active. Kardigan, a cardiovascular biotech, raised a substantial amount in an upsized IPO, pricing at the top of its range — joining a notable cohort of drug startups this year to achieve significant fundraising milestones, per BioPharma Dive. cAMPfield launched with a hundred-and-eighty-million-dollar Series A targeting oral alternatives to biologics in IBD. And Legend Biotech priced a two-hundred-twenty-six-million-dollar offering, with shares falling on dilution concerns.

Legend raising that kind of capital while still in the thick of the Carvykti commercial ramp — the dilution stings short-term, but it signals they see near-term needs that outweigh the share-price cost. The tension for investors is clear: you want management teams that invest aggressively in commercial inflections, but you don't love absorbing the dilution to fund it. That's the trade-off Legend is making in real time.

Lilly, meanwhile, closed on 4E Therapeutics, a non-opioid pain bolt-on marking their tenth acquisition of twenty twenty-six. And Innoviva is reviving Lyndra Therapeutics' long-acting oral drug platform, with Bob Langer and Janet Woodcock among its advisors. When capital deploys into cardiovascular, GI, pain, cell therapy, and drug delivery on the same day, the market isn't picking a lane — it's pricing in a broad innovation cycle that still has room to run. Ten acquisitions for Lilly alone tells you the largest players see external innovation as a core strategic necessity, not a supplement to internal R&D.

On the regulatory front — Merck's Capvaxive picked up a label expansion today. The multi-valent pneumococcal conjugate vaccine is now approved for at-risk children and adolescents who have completed their primary PCV series — positioning it as supplemental coverage with expanded serotype breadth beyond what the standard pediatric schedule delivers. For Merck, this deepens the commercial moat around Capvaxive by extending the addressable population into a segment where serotype coverage gaps have been a real clinical concern.

Also worth noting on the regulatory side — the FTC is requiring Aurobindo to divest four drug products to close its Lannett acquisition. Standard mechanics for a generics consolidation, but it confirms the FTC is actively policing concentration in the generic space — particularly in a year where generic M&A has been this active. The signal to other generic acquirers is straightforward: expect divestitures as a condition of closing, and build that into your deal models from the start.

And a policy story worth flagging early. Endpoints reports the Treasury Department is actively assessing options to screen outbound U.S. investments in China's biotech sector. Still early-stage, but if formal screening mechanisms take shape, cross-border licensing and venture co-investment between U.S. and Chinese biotech could look materially different within a year — and companies with Asia-facing partnering strategies would need to rethink the playbook. The implications run both directions — U.S. biotechs that have relied on China-based CROs or manufacturing partners could face new compliance layers, and Chinese biotechs seeking U.S. venture capital could find that capital materially harder to access.

Looking ahead — the marquee date is now August fifth, Moderna's mFlusiva PDUFA, following today's unanimous endorsement. Given that unanimity, the probability of an approval on or before that date is about as high as it gets in this business — though the specific label language, particularly around the sixty-five-plus accelerated approval conditions, will be worth reading closely. Also on the calendar: Pfizer CFO Dave Denton steps down August fifteenth for a role in consumer goods. PFE shares dropped nearly three percent on the news today. Cecile Guegan, currently SVP of Finance for the biopharma division, takes the interim CFO seat while the permanent search runs.

Whoever lands that permanent role inherits one of pharma's most complex financial restructurings — Eliquis and Ibrance revenue declining, the post-COVID portfolio still finding commercial footing, and a capital allocation strategy that demands a steady architect. The caliber of that hire will say a great deal about where Pfizer thinks it's headed. If they go external and recruit from outside pharma, that signals a desire for fresh strategic thinking. If they elevate Guegan permanently, it signals continuity and institutional knowledge as the priority. Either way, the choice will be one of the more telling executive decisions in big pharma this year.

That's your Pharma Closeout for Thursday. Moderna's unanimous panel win on mFlusiva, NovoCure's TRIDENT miss in glioblastoma, Biogen's billion-dollar immunology bet, and a capital market that keeps finding new bets to make. If this briefing saves you time, follow us on Spotify and drop a rating — we're back tomorrow with more.

Enjoy your evening. See you tomorrow. ## EPISODE METADATA **Title:** Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM; Biogen's $1B RayThera Deal | Jun 18, 2026 **Description:** Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B; Kardigan IPO raises $400M. **Tags:** Moderna, mFlusiva, MRNA, VRBPAC, mRNA flu vaccine, NovoCure, NVCR, TRIDENT, glioblastoma, TTFields, Biogen, BIIB, RayThera, immunology, Pfizer, PFE, CFO, Kardigan, IPO, cAMPfield, Legend Biotech, LEGN, Carvykti, Eli Lilly, 4E Therapeutics, Merck, Capvaxive, pneumococcal vaccine, Innoviva, Lyndra, Aurobindo, Lannett, FTC, Treasury, China biotech, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #